source
- J&J sees Spravato sales surge as psychedelic competitors loomPsychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.BioSpace · 13d ago↗ source
- Updated: Sanofi, Arbutus file separate suits against mRNA vaccine makers over LNP tech patentsSanofi and Arbutus are each going to court over alleged violations of their respective mRNA delivery patents, adding to a growing list of companies making similar complaints. The French pharma is s…Endpoints · 13d ago↗ source
- Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyEli Lilly said on Thursday it will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, in a move that further spotlights big pharma’s increasing interest in the space after years o…